Survodutide (BI 456906) is a 29-amino acid dual agonist peptide that activates both the glucagon-like peptide-1 (GLP-1) and glucagon receptors. Developed by Boehringer Ingelheim in partnership with Zealand Pharma, it represents a fundamentally different approach to obesity and metabolic disease: rather than suppressing appetite alone, survodutide simultaneously increases energy expenditure through the glucagon axis while reducing food intake through GLP-1 signaling. Phase 2 data has demonstrated up to 18.7% weight loss in obesity and a 62% MASH resolution rate — the highest biopsy-confirmed result in any liver disease trial to date.
What Is Survodutide?
Survodutide is an investigational once-weekly subcutaneous injection being developed for two primary indications: obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). It belongs to a growing class of multi-receptor agonists that target more than one incretin or metabolic pathway simultaneously.
- Drug class: Dual GLP-1/glucagon receptor agonist
- Developer: Boehringer Ingelheim (originated by Zealand Pharma)
- Structure: 29-amino acid peptide derived from the glucagon backbone, with key amino acid substitutions at positions 18, 20, and 23 that confer GLP-1 receptor activity
- Half-life: Approximately 109-115 hours (~4.5-4.8 days), enabled by a C18 diacid albumin-binding moiety
- Administration: Once-weekly subcutaneous injection
- FDA status: Investigational — not approved. Breakthrough Therapy Designation for MASH (September 2024)
How Survodutide Compares
| Feature | Semaglutide | Tirzepatide | Survodutide | Retatrutide |
|---|---|---|---|---|
| Targets | GLP-1 only | GLP-1 + GIP | GLP-1 + Glucagon | GLP-1 + GIP + Glucagon |
| Peak weight loss | ~15% | ~21% | ~18.7% | ~24.2% |
| Energy expenditure | No | No | Yes (glucagon) | Yes (glucagon) |
| Liver fat effect | Moderate | Moderate | Potent (direct) | Potent (direct) |
| FDA status | Approved | Approved | Phase 3 | Phase 3 |
How It Works
Survodutide's dual mechanism targets two complementary metabolic pathways:
GLP-1 Receptor Agonism
The GLP-1 component reduces appetite through central satiety signaling, slows gastric emptying to promote fullness, and enhances glucose-dependent insulin secretion. This is the same mechanism used by semaglutide and tirzepatide. Survodutide's GLP-1 receptor potency (EC50 = 20 pM) is approximately 4-fold lower than native GLP-1 (5 pM), making it a moderate GLP-1 agonist rather than a dominant one.
Glucagon Receptor Agonism
The glucagon component is what differentiates survodutide from GLP-1-only agents. Glucagon receptor activation increases hepatic lipid oxidation (burning liver fat for energy), raises resting energy expenditure, and promotes thermogenesis. The glucagon receptor potency (EC50 = 108 pM) is approximately 22-fold lower than native glucagon, providing a balanced dual agonist profile rather than a glucagon-dominant one.
This combination means survodutide attacks obesity from both sides: reduced caloric intake through GLP-1 and increased caloric expenditure through glucagon. The hepatic effects of glucagon also make it uniquely suited for MASH, where liver fat accumulation is the core pathology.
Research Evidence
Phase 2 Obesity Trial (Lancet Diabetes & Endocrinology, 2023)
A randomized, double-blind, placebo-controlled dose-finding trial in adults with BMI ≥27 without type 2 diabetes tested four doses of survodutide (0.6, 2.4, 3.6, and 4.8 mg) over 46 weeks (20 weeks dose escalation + 26 weeks maintenance):
- 0.6 mg: 6.2% weight loss
- 2.4 mg: 12.5% weight loss
- 3.6 mg: 13.2% weight loss
- 4.8 mg: 14.9% weight loss (vs 2.8% placebo)
- 4.8 mg treatment completers: 18.7% weight loss
At the highest dose, 83% of participants lost ≥5% body weight, 69% lost ≥10%, and 55% lost ≥15%.
Phase 2b MASH Trial (New England Journal of Medicine, 2024)
The landmark MASH trial enrolled patients with biopsy-confirmed MASH and fibrosis stages F1-F3. After 48 weeks of treatment, results on the primary endpoint of MASH improvement without fibrosis worsening were:
- 2.4 mg: 47% (vs 14% placebo)
- 4.8 mg: 62% (vs 14% placebo)
- 6.0 mg: 43% (vs 14% placebo)
The 62% MASH resolution rate at the 4.8 mg dose is the highest reported in any randomized controlled MASH trial. Liver fat reduction of ≥30% was achieved in 67% of participants at 4.8 mg (vs 14% placebo). Fibrosis improvement of ≥1 stage occurred in 36% at 4.8 mg (vs 22% placebo), rising to 64.5% in the F2/F3 subgroup at 6 mg.
Head-to-Head vs Semaglutide
In a Phase 2 trial comparing survodutide to open-label semaglutide 1.0 mg in patients with type 2 diabetes (published in Diabetologia, 2024), survodutide ≥1.8 mg produced 8.7% weight loss versus 5.3% for semaglutide at 16 weeks, with comparable or superior HbA1c reductions at higher doses.
Phase 3 Program (SYNCHRONIZE)
Boehringer Ingelheim's Phase 3 program includes multiple large-scale trials:
- SYNCHRONIZE-1 (NCT06066515): 726 participants with obesity, no T2DM. Testing 3.6 mg and 6 mg vs placebo over 76 weeks. Topline data expected H1 2026.
- SYNCHRONIZE-2 (NCT06066528): Obesity with T2DM. Same doses, 76 weeks. Topline expected H1 2026.
- SYNCHRONIZE-CVOT (NCT06077864): 5,508 participants with obesity and established CV disease or CKD. Primary endpoint: 5-point MACE. Conducted across 34 countries and 524 sites.
- LIVERAGE (NCT06632444): ~1,800 participants with MASH and F2/F3 fibrosis. 52-week efficacy endpoint with ~7 year long-term follow-up.
Phase 3 trials use 4-week dose escalation intervals (vs 2-week in Phase 2) to reduce gastrointestinal side effects.
Dosing Protocol
Survodutide is administered as a once-weekly subcutaneous injection.
Phase 2 Escalation (2-Week Intervals)
| Week | Dose |
|---|---|
| 1-2 | 0.3 mg |
| 3-4 | 0.9 mg |
| 5-6 | 1.8 mg |
| 7-8 | 2.7 mg |
| 9-10 | 3.6 mg |
| 11+ | 4.8 mg (maintenance) |
Phase 3 Escalation (4-Week Intervals)
Phase 3 trials use slower 4-week escalation intervals to improve tolerability, with target maintenance doses of 3.6 mg or 6.0 mg. The specific step-by-step Phase 3 titration schedule has not been fully disclosed.
Side Effects
Gastrointestinal adverse events are the primary concern with survodutide, consistent with other GLP-1 receptor agonists:
| Side Effect | Survodutide (Phase 2) | Placebo |
|---|---|---|
| Any GI disorder | 75% | 42% |
| Nausea | 66% | 23% |
| Diarrhea | 49% | 23% |
| Vomiting | 41% | 4% |
| Discontinuation (all causes) | 20-25% | 3-4% |
Approximately 72% of discontinuations occurred during the first 6 weeks of dose escalation. Serious adverse events were actually lower in the survodutide group (4%) than placebo (7%). The Phase 3 trials use slower dose titration (4-week intervals vs 2-week) to substantially reduce these dropout rates.
The GI side effect profile is notably higher than semaglutide (~4% discontinuation) and tirzepatide (~7% discontinuation), making tolerability the key competitive question for survodutide's obesity indication.
Legal Status
Survodutide is an investigational drug that has not been approved by any regulatory agency worldwide.
Regulatory Designations
- FDA Breakthrough Therapy Designation for noncirrhotic MASH with moderate-to-advanced fibrosis (September 2024)
- FDA Fast Track Designation for MASH (September 2024)
- EMA PRIME Designation for MASH (2024)
- China Breakthrough Therapy Designation for MASH with fibrosis (2024)
Expected Timeline
- Phase 3 obesity topline data: H1 2026
- Earliest NDA submission: Late 2026 or 2027 (MASH, with Breakthrough Therapy for accelerated review)
- Potential FDA approval: 2027-2028 for MASH; obesity timeline dependent on Phase 3 results
Survodutide is not available through compounding pharmacies, research chemical suppliers, or any legitimate commercial channel. Any product marketed as survodutide is unverified and potentially dangerous.